ABOUT CHDR
The Centre for Human Drug Research (CHDR) is an independent, full-service contract research organisation (CRO) that specialises in cutting-edge, early phase clinical drug research in both healthy volunteers and small patient cohorts, across a wide range of therapeutic areas. CHDR develops and uses state-of-the-art methods and research tools to collect as much information as possible about candidate drugs in the early phases of clinical development, helping sponsors make informed decisions regarding the further development of their product. The company serves as a ‘one-stop-shop’, offering end-to-end CRO solutions for early phase programs. In addition, CHDR operates a purpose-built, state-of-the-art phase 1 unit with 54 beds, as well as a hospital-based unit consisting of 8 beds.
FEATURED CONTENT
-
![GettyImages-2036497889-lab-computer-research]( "Best Practices For Evaluating Immunologically Active Compounds")
Gain insight into the evolving landscape of immune-based drug development and best practices CROs should adopt to overcome its unique challenges.
-
![GettyImages-1648451466-scientist-cell-culture-laboratory-pipette-research]( "Early Immune Profiling With In Vivo, In Vitro, And Ex Vivo Systems")
Modern biologics increasingly interact with the immune system. While these innovations enable transformative therapies, they can also provoke acute immune activation during first-in-human (FIH) trials.
-
![EHealth, electronic health-GettyImages-999117226]( "What Do Cancer Patients Really Want From mHealth Technology?")
What do cancer patients really want from apps and wearables? This piece reveals how patient perspectives can guide mHealth design to reduce burden, build trust, and make digital oncology tools truly meaningful.
-
![GettyImages-1130026826 doctor patient centricity]( "Rethinking Recruitment: Patient-Centric Strategies For The Future Of Clinical Trials")
For sponsors and CROs, the message is clear: recruitment must be redesigned for accessibility, inclusivity, and patient trust.
-
![GettyImages-1025834378-manufacturing-excipient-drug-pharma]( "Navigating Adverse Immunostimulation: A Practical Guide For Clinical Researchers")
Explore a systematic approach to evaluate adverse immunostimulation (AIS) in drug development through standardized biomarker sampling and tailored management strategies.
-
![GettyImages-2032712798-lab-vaccine-microscope-research-development]( "Leveraging Biomarkers In Early PK/PD Studies")
Integrating biomarkers into early clinical studies is crucial to determine whether a new therapy engages its biological target, triggers the intended PD effects, and shows early signs of efficacy.
-
![GettyImages-1471734234-derm-dermatology-skin]( "Blueprint For Early Phase Clinical Pharmacology Studies In Dermatology")
Explore the landscape of dermatological drug development through a comprehensive framework for rational early-phase dermatological trials, centered around five foundational pillars.
-
![GettyImages-2081140990-phone-cellphone-hand]( "A Smartphone Based Biomarker For The Estimation Of Unipolar Depression Severity")
The study investigates the potential of using smartphones and wearables to create objective biomarkers for mood disorders, specifically focusing on unipolar depression.
-
![GettyImages-1693748594 phone]( "Remote Patient Monitoring Using Mobile Health Technology")
This study investigates the attitudes of cancer patients towards the adoption of mHealth technologies, including applications and wearable devices, for monitoring purposes during or after their treatment.
CONTACT INFORMATION
CHDR
Zernikedreef 8
Leiden, 2333 CL
NETHERLANDS
Phone: +31 715246430
Contact: Wouter ten Voorde
CHDR SOLUTIONS
-
![Human Immune System GettyImages-1201363459]( "Immune Challenge Models For Early Drug Development")
Inflammation is a primary pathogenic process in a wide range of diseases, including rheumatoid arthritis, cardiovascular disease, oncology and neuropsychiatric disorders.
-
![GettyImages-1391303942 patient doctor HCP]( "Clinical Pharmacokinetics And Pharmacometrics")
Learn about a sophisticated suite of pharmacokinetic (PK) and pharmacometric services designed to accelerate and optimize early-phase drug development.
-
![EU Regulations, europe union flag-GettyImages-1175944437]( "Clinical Trial Regulations")
This essential guide walks through mastering the complex landscape of clinical trial regulations, providing a clear, practical breakdown of regulatory timelines, legal obligations, and more.
-
![GettyImages-1325251634-doctor-patient-blood-pressure-visit]( "Recruitment Strategies: A Behind The Scenes Look")
Explore a dynamic recruitment strategy being used to address the growing demand for participants in early-stage clinical trials while overcoming regulatory and ethical challenges.
-
![iStock-1152216276-skin-dermatology]( "Innovative Dermatological Assessments For Early Drug Development")
Our dermatology studies provide results that are more than skin deep. Because the skin is the largest and most easily accessible organ, our dermatology research also facilitates drug development in other areas, including immunology and endocrinology. In addition, we are engaged in studying ways to improve wound healing.
-
![Human Brain cerebellum-GettyImages-2150929983]( "Gain Objective Measures And Subjective Measures Of CNS Function")
NeuroCart is a fully self-contained, mobile CNS test battery developed in-house at CHDR, offering the possibility to measure a wide range of CNS effects in a pharmacological context.
-
![CHDR neuro feature]( "Measuring A Wide Range Of CNS Effects In A Pharmacological Context")
With nearly three decades of successful application, NeuroCart remains a gold standard in CNS pharmacology, supporting precise, data-driven decisions in drug development.
-
![cell phone data iStock-1274394138]( "Enable Value-Based Evaluation Of Medicines")
Trial@home, CHDR’s dedicated strategy for off-site clinical trials, enables investigators to collect information as trial participants go about their day to day activities.
